Effects of the multi‐kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia

Recently, several targeted agents have been developed for specific subsets of patients with acute myeloid leukaemia (AML), including midostaurin, the first FDA‐approved FLT3 inhibitor for newly diagnosed patients with FLT3 mutations. However, in the initial Phase I/II clinical trials, some patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Weisberg, Ellen, Meng, Chengcheng, Case, Abigail E., Tiv, Hong L., Gokhale, Prafulla C., Buhrlage, Sara J., Yang, Jing, Liu, Xiaoxi, Wang, Jinhua, Gray, Nathanael, Adamia, Sophia, Sattler, Martin, Stone, Richard, Griffin, James D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077552/
https://www.ncbi.nlm.nih.gov/pubmed/31967735
http://dx.doi.org/10.1111/jcmm.14927

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077552/
https://www.ncbi.nlm.nih.gov/pubmed/31967735
http://dx.doi.org/10.1111/jcmm.14927

Ejemplares similares